Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast to 2027

Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast to 2027

  • January 2018 •
  • 50 pages •
  • Report ID: 5299590
DelveInsight’s "Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Metastatic Renal Cell Carcinoma (mRCC) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2027

Metastatic Renal Cell Carcinoma (mRCC) Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Metastatic Renal Cell Carcinoma (mRCC) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Metastatic Renal Cell Carcinoma (mRCC) outlook. It also includes the explanation of changing trends of epidemiology outlining the Metastatic Renal Cell Carcinoma (mRCC) scenario.

Metastatic Renal Cell Carcinoma (mRCC) Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Metastatic Renal Cell Carcinoma (mRCC) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Metastatic Renal Cell Carcinoma (mRCC) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Metastatic Renal Cell Carcinoma (mRCC) Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Metastatic Renal Cell Carcinoma (mRCC)

Key assessments
• Patient Segmentation in Metastatic Renal Cell Carcinoma (mRCC)
• Metastatic Renal Cell Carcinoma (mRCC) Risk & Burden
• Factors driving growth in a specific Metastatic Renal Cell Carcinoma (mRCC) patient population
Country=France Industry=Cancer ParentIndustry=LifeSciences Date=201801 Publisher=DelveInsight Price=3000